InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...
Nepal: Pyoderma gangrenosum (PG) can occur without associated systemic disease and may resemble infectious or vascular ulcers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results